Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AI therapies

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer

Approximately 210,000 people worldwide are diagnosed with the disease every year

- PMLiVE

ICR scientists reveal new ways to convert inhibitor-style targeted cancer drugs into degraders

Findings from the study could help researchers create more effective treatments for cancer

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

- PMLiVE

Sanofi announces UK launch of inactivated rabies vaccine Verorab for all age groups

The rare neurotrophic virus is responsible for an estimated 59,000 global deaths every year

- PMLiVE

BMS and Shine Cancer Support’s UK research reveals disparities in cancer diagnosis

The Cancer Equals campaign and 1,000 Voices, Not 1 report aim to help address reasons for diagnostic delays

- PMLiVE

Scientists recommend new imaging technique to support design of innovative cancer drugs

Cryo-EM helped to determine the detailed structures of CAK, a promising target for cancer drugs

- PMLiVE

New study reveals discrepancies in FDA accelerated approval process for cancer drugs

The study looked at 46 different cancer drugs that received accelerated approvals between 2013 and 2017

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

- PMLiVE

Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

- PMLiVE

Merck KGaA and Caris enter oncology partnership worth over $1.4bn

The alliance is aimed at accelerating the development of ADCs for cancer patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links